Pharmaceuticals was among the leaders in growth among Russian business sectors

Such ratings have been compiled by the company for the fifth year in a row. This year, representatives of 33 industries came here. At the same time, private companies got 407 places. Another 75 took state, 7 - with significant state and foreign participation, another 7 - private companies with significant state participation and 4 private companies with a significant share of foreign ownership. The first places, as in the past ranking, were taken by Gazprom and Rosneft, changing places.

It is worth noting that in 2020, the total income of the 500 largest companies decreased by 4.9% and reached 84.9 trillion rubles. At the same time, the permanent leader - the oil and gas sector - reduced the indicator by 24%, and its share of the total revenue of all companies represented in the rating settled at 28.7% compared to 36.2% of the previous ones. The retail sector, which took second place, fell 11.4%. Finishing in the "prizes" the financial sector showed 11.3%. RBC notes that in 2020, the 500 largest companies, for the first time since 2015, reduced their total income by 4.9%. At the same time, the amount still reached 84.9 trillion rubles.

Among the positive points, the compilers of the rating highlighted the areas of information technology with an increase of 30.7%. Agriculture and food, together with pharmaceuticals, showed figures of + 23.6 and + 21.7%, respectively. At the same time, the revenue of pharmaceuticals was at the level of 1.3 trillion rubles.

This positive dynamics for pharmaceuticals is explained by Anton Zybin, General Director of Lancet JSC, a company that took 396 positions and rose in the ranking immediately by 24 lines compared to last year:

"It is obvious that the negative dynamics in the total revenue of companies represented in the RBC 500 rating is associated with the COVID-19 pandemic and quarantine restrictions. At the same time, the pharmaceutical industry has grown quite logically, and our company is a confirmation of this. We confidently continue to increase turnover (According to the compilers of the rating, the company's total revenue grew by 18% and amounted to 32 billion rubles, - ed.) Especially in the sectors of our traditional leadership: blood management drugs, anesthesia and resuscitation. Strengthening the Lancet's position in other areas will allow us to rise a few more positions higher next year. "